• In early May 2026, Gilead Sciences reported first-quarter revenue of US$6.96 billion and net income of US$2.02 billion, while also completing a multi-year US$4.57 billion share repurchase program and filing a US$6.51 billion shelf registration for up to 47,750,000 common shares.
• At the same time, the FDA accepted Gilead’s New Drug Application for its once-daily bictegravir/lenacapavir HIV regimen with priority review, underscoring how strong HIV portfolio performance and an advancing pipeline coexist with a sharply lower full-year earnings forecast driven by large acquisition-related charges.
• We’ll now examine how stronger revenue guidance alongside acquisition-driven pressure on earnings reshapes Gilead’s investment narrative around cash generation and pipeline.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

Gilead Sciences Investment Narrative Recap

To own Gilead today, you need to believe that its HIV franchise and expanding pipeline can keep funding dividends and reinvestment, even as policy and competition risks build. The latest quarter reinforces that tension: higher product sales and stronger HIV momentum support the cash generation story, while the sharply lowered full year earnings outlook and acquisition charges highlight how execution and capital allocation remain the key near term swing factors.

Among the recent developments, the FDA’s priority review of Gilead’s once daily bictegravir/lenacapavir HIV regimen stands out. It speaks directly to the core catalyst of extending HIV leadership with next generation regimens that could refresh the portfolio ahead of later patent expiries. How that opportunity balances against heightened earnings pressure from recent deals and potential future pricing reforms is what investors will be watching most closely.

Yet beneath the strong HIV data, investors should be aware of how a sudden earnings swing into loss guidance could interact with...

Gilead Sciences' narrative projects $33.6 billion revenue and $10.9 billion earnings by 2029. This requires 4.5% yearly revenue growth and a $2.4 billion earnings increase from $8.5 billion today.

Uncover how Gilead Sciences' forecasts yield a $157.43 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were assuming Gilead’s revenue would grow only about 2.4% annually to roughly US$31.6 billion by 2029, so if you worry about oncology competition capping growth, their more pessimistic view shows just how differently reasonable people can read the same story and why fresh results like this quarter may shift those expectations.

Explore 5 other fair value estimates on Gilead Sciences - why the stock might be worth just $128.42!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Gilead Sciences research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Gilead Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Gilead Sciences' overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 33 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.